Renal denervation and advanced imaging modalities play an important role in managing and diagnosing cardiac pathology in patients with resistant hypertension.
Answers are grounded in this paper and cite their sources.
Supports role of renal denervation and imaging in resistant hypertension; leaves open need for randomized cardiac outcome trials.
Patients with resistant arterial hypertension have a high prevalence of cardiac pathology. In particular, left ventricular hypertrophy and reduced coronary reserve play independent role in determining the risk of cardiovascular complications. Diagnostic approaches to their detection are currently represented by a wide range of highly informative studies using modern ultrasound equipment, magnetic resonance imaging, computed tomography scanner, and gamma camera. The active study of the involvement of the cascade of pathophysiological mechanisms in the development of cardiac changes in hypertension allows not only to identify the factors associated with the severity of the lesion, but also to find new application points for the cardioprotection and to reduce cardiovascular risk. Along with the pharmacological capabilities, the renal denervation method is currently under active study. Despite high variability of the results and their poor predictability, a number of studies show the efficiency of this method in correcting the structural and functional changes in the heart, which is of important prognostic value for resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Mordovin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: